Document center

Report on COVID-19 impact on gender equality in research and innovation (2023)

Published on | 2 years ago

Programmes Enhancing EU R&I

This report presents the findings of the European Commission’s Expert Group on the COVID-19 impact on gender equality in Research and Innovation (R&I). The report highlights in particular the pandemic’s gendered impact on academic productivity, early career researchers (ECRs), and work-life balance. It investigates institutional responses and aims to bring forward unseen and marginalised experiences in academia. The recommendations are intended for R&I policymakers at national and EU-level, research funding organisations and research performing organisations. They present an opportunity for Member States and R&I organisations to apply the lessons learnt from the pandemic to the development of inclusive gender equality policies in the European Research Area (ERA). (from the report’s back cover)

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.